Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1980 32
1981 73
1982 108
1983 97
1984 93
1985 74
1986 88
1987 76
1988 63
1989 88
1990 86
1991 80
1992 85
1993 79
1994 93
1995 88
1996 77
1997 75
1998 67
1999 55
2000 52
2001 49
2002 44
2003 56
2004 53
2005 53
2006 49
2007 46
2008 44
2009 51
2010 55
2011 61
2012 44
2013 63
2014 59
2015 65
2016 73
2017 72
2018 92
2019 119
2020 83
Text availability
Article attribute
Article type
Publication date

Search Results

2,699 results
Results by year
Filters applied: . Clear all
Page 1
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Murphy SM, et al. Ann Intern Med. 2019 Jan 15;170(2):90-98. doi: 10.7326/M18-0227. Epub 2018 Dec 18. Ann Intern Med. 2019. PMID: 30557443 Free PMC article. Clinical Trial.
BACKGROUND: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder. ...PRIMARY FUNDING SOURCE: National Institute on Drug Abuse, National Institutes of Health....
BACKGROUND: Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use dis …
Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
Fairbairn N, Coffin PO, Walley AY. Fairbairn N, et al. Int J Drug Policy. 2017 Aug;46:172-179. doi: 10.1016/j.drugpo.2017.06.005. Epub 2017 Jul 4. Int J Drug Policy. 2017. PMID: 28687187 Free PMC article.
We present current challenges arising in this new era of synthetic opioids, including variable potency of illicit drugs due to erratic adulteration of the drug supply with synthetic opioids, potentially changing efficacy of standard naloxone formulations for overdos …
We present current challenges arising in this new era of synthetic opioids, including variable potency of illicit drugs due to erratic adult …
A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice.
Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. Mueller SR, et al. Subst Abus. 2015;36(2):240-53. doi: 10.1080/08897077.2015.1010032. Epub 2015 Mar 16. Subst Abus. 2015. PMID: 25774771 Free PMC article. Review.
Naloxone hydrochloride (naloxone), an opioid antagonist, is the standard of care for treatment of opioid induced respiratory depression. ...RESULTS: We identified 41 articles that represented 5 categories: evaluations of OEND programs, effects of OEND programs on ex
Naloxone hydrochloride (naloxone), an opioid antagonist, is the standard of care for treatment of opioid induced respiratory d
Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, Dale O. Strang J, et al. Drugs. 2019 Sep;79(13):1395-1418. doi: 10.1007/s40265-019-01154-5. Drugs. 2019. PMID: 31352603 Free PMC article. Review.
Naloxone is a well-established essential medicine for the treatment of life-threatening heroin/opioid overdose in emergency medicine. ...The provision of take-home naloxone has required the introduction of new legislation and new naloxone products. These incl
Naloxone is a well-established essential medicine for the treatment of life-threatening heroin/opioid overdose in emergency medicine.
Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
Wheeler E, Jones TS, Gilbert MK, Davidson PJ; Centers for Disease Control and Prevention (CDC). Wheeler E, et al. MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):631-5. MMWR Morb Mortal Wkly Rep. 2015. PMID: 26086633 Free PMC article.
Drug overdose deaths in the United States have more than doubled since 1999. During 2013, 43,982 drug overdose deaths (unintentional, intentional [suicide or homicide], or undetermined intent) were reported. ...In July 2014, the Harm Reduction Coalition (HRC), a
Drug overdose deaths in the United States have more than doubled since 1999. During 2013, 43,982 drug overdose deaths (uninten
Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA.
Bessen S, Metcalf SA, Saunders EC, Moore SK, Meier A, McLeman B, Walsh O, Marsch LA. Bessen S, et al. Int J Drug Policy. 2019 Dec;74:144-151. doi: 10.1016/j.drugpo.2019.09.008. Epub 2019 Oct 4. Int J Drug Policy. 2019. PMID: 31590090
CONCLUSION: Opioid users' and emergency responders' perceptions about naloxone may limit the optimal use of naloxone within the community. This study identifies opportunities to address misconceptions about naloxone and challenges in accessing naloxone
CONCLUSION: Opioid users' and emergency responders' perceptions about naloxone may limit the optimal use of naloxone within th …
Compulsive-Like Sufentanil Vapor Self-Administration in Rats.
Vendruscolo JCM, Tunstall BJ, Carmack SA, Schmeichel BE, Lowery-Gionta EG, Cole M, George O, Vandewater SA, Taffe MA, Koob GF, Vendruscolo LF. Vendruscolo JCM, et al. Neuropsychopharmacology. 2018 Mar;43(4):801-809. doi: 10.1038/npp.2017.172. Epub 2017 Aug 16. Neuropsychopharmacology. 2018. PMID: 28812595 Free PMC article.
Rats that were given long access (LgA; 12 h/day) but not short access (ShA; 1 h/day) to vaporized sufentanil escalated their drug intake over time and exhibited both naloxone-precipitated somatic signs of opioid withdrawal and spontaneous withdrawal-induced mechanic …
Rats that were given long access (LgA; 12 h/day) but not short access (ShA; 1 h/day) to vaporized sufentanil escalated their drug int …
Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
Neumann AM, Blondell RD, Hoopsick RA, Homish GG. Neumann AM, et al. J Addict Dis. 2020 Jan-Mar;38(1):33-41. doi: 10.1080/10550887.2019.1690929. Epub 2019 Nov 27. J Addict Dis. 2020. PMID: 31774028
Nineteen participants were randomly assigned to methadone or buprenorphine/naloxone and were followed for 6 months. In an intent-to-treat analysis analgesia, craving, functioning, drug use, depression, and treatment retention were assessed monthly. It was planned to …
Nineteen participants were randomly assigned to methadone or buprenorphine/naloxone and were followed for 6 months. In an intent-to-t …
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. Ling W, et al. Addiction. 2016 Aug;111(8):1416-27. doi: 10.1111/add.13375. Epub 2016 Apr 21. Addiction. 2016. PMID: 26948856 Free PMC article. Clinical Trial.
METHODS: This multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Ge …
METHODS: This multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abu
Adoption and Utilization of an Emergency Department Naloxone Distribution and Peer Recovery Coach Consultation Program.
Samuels EA, Baird J, Yang ES, Mello MJ. Samuels EA, et al. Acad Emerg Med. 2019 Feb;26(2):160-173. doi: 10.1111/acem.13545. Epub 2018 Oct 3. Acad Emerg Med. 2019. PMID: 30074673 Free article.
Primary study outcomes were take-home naloxone provision and recovery coach consultation. Secondary study outcome was referral to treatment. ...Take-home naloxone provision and recovery coach consultation did not depreciate over time. CONCLUSIONS: ED naloxone
Primary study outcomes were take-home naloxone provision and recovery coach consultation. Secondary study outcome was referral to tre …
2,699 results
Jump to page
Feedback